$PTIX

ARMEN GARO H purchased $151 of PTIX

ARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF) purchased 685 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.22 on 2026-08-06.

Original reporting
SEC EDGAR · ARMEN GARO H
Published Aug 10, 2026, 2:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 2:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PTIX
Neutral
low confidence
Mentioned
$PTIX
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PTIXNeutralLow
01

Why it matters

An insider open-market purchase is disclosed, but the transaction value is small and the filing contains no additional operational or financial updates.

02

Market read

Traders may note the insider buy, but the disclosed size and lack of accompanying catalysts make it a low-conviction signal.

03

What to watch

No context is provided on prior insider activity, total insider ownership changes beyond the post-transaction figure, or any concurrent company-specific catalysts.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-10 after-hours/market close window (per timestamp)

Background

The article is a SEC Form 4 insider transaction disclosure for Protagenic Therapeutics, Inc.

Company-level read

Ticker impact

$PTIXNeutralLow confidence
Context

Protagenic Therapeutics disclosed an insider open-market purchase by its Executive Chair and Principal Officer: 685 shares at $0.2200 on 2026-08-06.

Expected impact

Low likelihood of a sustained price move based solely on this filing.

Evidence & confidence

The filing is a disclosed insider transaction, but the disclosed size ($150.70) is small and there is no 10b5-1 plan or other accompanying corporate catalyst in the text.

Market effects

No clear sector read-through from a small insider buy in a single issuer.

None indicated.

None indicated.

Counterpoint

The buy may reflect personal liquidity planning or routine compensation-related activity rather than a strong forward-looking view.

Key entities

  • Protagenic Therapeutics, Inc.

    Company subject of the Form 4 insider transaction disclosure (PTIX).

  • ARMEN GARO H

    Executive Chair and Principal Officer who purchased 685 shares at $0.2200 on 2026-08-06.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PTIXMedAI 8/10

Protagenic Therapeutics, Inc.: Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder

Protagenic Therapeutics (PTIX) received FDA feedback supporting its planned Phase 1 program for PT00114, a treatment for generalized anxiety disorder. The FDA raised no objections to the program design, dose-escalation approach, or CMC and nonclinical packages. The company plans to submit the IND before the end of 2026 and target first patient dosing in the first half of 2027. PT00114 has shown promising results in preclinical and early-phase studies.

$PTIXMed

Original-Research: Pentixapharm Holding AG (von NuWays AG): BUY

^ Original-Research: Pentixapharm Holding AG - from NuWays AG 31.07.2026 / 09:00 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.